×







We sell 100% Genuine & New Books only!

Translational Research Methods In Diabetes, Obesity, And Nonalcoholic Fatty Liver Disease : A Focus On Early Phase Clinical Drug Development 2Nd Edition 2019 at Meripustak

Translational Research Methods In Diabetes, Obesity, And Nonalcoholic Fatty Liver Disease : A Focus On Early Phase Clinical Drug Development 2Nd Edition 2019 by Andrew J Krentz, Springer

Books from same Author: Andrew J Krentz

Books from same Publisher: Springer

Related Category: Author List / Publisher List


  • Price: ₹ 15087.00/- [ 25.00% off ]

    Seller Price: ₹ 11315.00

Estimated Delivery Time : 4-5 Business Days

Sold By: Meripustak      Click for Bulk Order

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

We deliver across all postal codes in India

Orders Outside India


Add To Cart


Outside India Order Estimated Delivery Time
7-10 Business Days


  • We Deliver Across 100+ Countries

  • MeriPustak’s Books are 100% New & Original
  • General Information  
    Author(s)Andrew J Krentz
    PublisherSpringer
    Edition2nd
    ISBN9783030117474
    Pages556
    BindingHardcover
    LanguageEnglish
    Publish YearMay 2019

    Description

    Springer Translational Research Methods In Diabetes, Obesity, And Nonalcoholic Fatty Liver Disease : A Focus On Early Phase Clinical Drug Development 2Nd Edition 2019 by Andrew J Krentz

    "This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders.

     Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs.

     This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic d..."



    Book Successfully Added To Your Cart